Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
	Form 144
FORM 144	NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK	0001819718
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	◉ LIVE ○ TEST

Submission Contact Information

Name	
Phone	
E-Mail Address	

144: Issuer Information

Name of Issuer	FULGENT GENETICS, INC.
SEC File Number	001-37894
Address of Issuer	4399 Santa Anita Ave El Monte CALIFORNIA 91731
Phone	626-350-0537
Name of Person for Whose Account the Securities are To Be Sold	Xie Jian

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC 1 New York Plaza, 38th FL New York NY 10004	1198	36119.7	30912392	11/28/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition	Name of Person from	Is this	Date Donor	Amount of Securities	Date of Payment	Nature of Payment *

		Transaction	Whom Acquired	a Gift?	Acquired	Acquired	
Common Stock	02/26/2024	Resticted stock vest	Fulgent Genetics, Inc.	☐	25350	02/26/2024	Equity compensation for services rendered

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Jian Xie C/O Fulgent Genetics, Inc. 4399 Santa Anita Avenue El Monte CA 91731	Common Stock	08/25/2025	696	14965.08
Jian Xie C/O Fulgent Genetics, Inc. 4399 Santa Anita Avenue El Monte CA 91731	Common Stock	08/27/2025	1199	25760.2
Jian Xie C/O Fulgent Genetics, Inc. 4399 Santa Anita Avenue El Monte CA 91731	Common Stock	09/03/2025	1128	24846.15
Jian Xie C/O Fulgent Genetics, Inc. El Monte CA 91731	Common Stock	11/19/2025	10000	290982.76
Jian Xie C/O Fulgent Genetics, Inc. El Monte CA 91731	Common Stock	11/24/2025	681	20752.08

144: Remarks and Signature

Remarks	These shares were sold to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units ("sell-to-cover" transactions). The transaction, as well as other sales over the past three months (excluding the November 19, 2025 sale), do not represent discretionary trades by the Reporting Person. The November 19, 2025 sale was executed solely for year-end tax-planning purposes.
Date of Notice	11/26/2025

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature /s/ Paul Kim as Attorney-in-Fact

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)